Likewise, CD39-targeting monoclonal antibodies have been shown to inhibit eADO production in the TME, effectively suppress metastasis, upregulate the expression of activation markers and cytotoxic granule components in immune cells, and increase the anti-tumor functions of infiltrating NK and T cells [55,56,57]. The gene discussed is ENTPD1; the disease is neoplasm.